Hoelzer Dieter, Gökbuget Nicola
J.W. Goethe University Hospital, Medical Clinic III, Theodor Stern Kai 7, 60590, Frankfurt, Germany.
Best Pract Res Clin Haematol. 2002 Dec;15(4):713-28. doi: 10.1053/beha.2002.0230.
Lymphoblastic lymphoma (LBL) is a rare subtype of non-Hodgkin's lymphoma (NHL) with biological features similar to those of acute lymphoblastic leukaemia. In the majority of cases LBL shows a T-cell phenotype, and mediastinal tumours are the most frequent manifestation. Outcomes of LBL patients treated according to NHL or ALL-type regimens are reviewed. Since prophylaxis of CNS relapse and local recurrence emerged as important issues in the treatment of LBL the different options are discussed. Several studies have used autologous stem cell transplantation (SCT) in the primary treatment of LBL and results are reviewed. The analysis of published prognostic factors and models in LBL demonstrates that, at present, no convincing risk model is available for LBL treated according to contemporary intensive chemotherapy protocols. Therefore indications for SCT in first complete remission (CR) cannot be defined. Future prospects for improvement of treatment results in LBL include intensification of chemotherapy, definition of prognostic factors, evaluation of minimal residual disease and SCT in high-risk patients.
淋巴母细胞淋巴瘤（LBL）是一种罕见的非霍奇金淋巴瘤（NHL）亚型，其生物学特征与急性淋巴细胞白血病相似。在大多数病例中，LBL表现为T细胞表型，纵隔肿瘤是最常见的表现形式。本文回顾了根据NHL或ALL型方案治疗的LBL患者的治疗结果。由于中枢神经系统复发和局部复发的预防已成为LBL治疗中的重要问题，因此对不同的选择进行了讨论。多项研究在LBL的初始治疗中使用了自体干细胞移植（SCT），并对结果进行了回顾。对已发表的LBL预后因素和模型的分析表明，目前，对于按照当代强化化疗方案治疗的LBL，尚无令人信服的风险模型。因此，无法确定首次完全缓解（CR）时进行SCT的指征。改善LBL治疗结果的未来前景包括强化化疗、确定预后因素、评估微小残留病以及对高危患者进行SCT。
